Valuation: Shamrock Industrial Company Limited

Market Cap 116M 1.22M 1.05M 984K 903K 1.7M 1.73M 11.55M 4.53M 58.14M 4.58M 4.48M 192M P/E 2024
-128x
P/E 2025 -53.4x
Enterprise Value 116M 1.22M 1.05M 983K 902K 1.7M 1.72M 11.54M 4.53M 58.07M 4.57M 4.47M 192M EV / Sales 2024
38,257,531x
EV / Sales 2025 -
Free-Float
48.09%
Yield 2024 *
-
Yield 2025 -
05-29 Shamrock Industrial Company Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-12 Shamrock Industrial Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
12-22 Shamrock Industrial Company Limited Approves the Proposals for Incorporation of Wholly Owned Subsidiaries CI
12-22 Shamrock Industrial Company Limited Approves the Proposals for Incorporation of Wholly Owned Subsidiaries CI
12-11 Shamrock Industrial Company Limited Announces Incorporation of Wholly Owned Subsidiary HODL Energy Private Limited in India CI
11-14 Shamrock Industrial Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
11-12 Lotus Excel Wealth Creators LLP, HODL Systems LLP, Bagepalli Vijaykumar Harish and Rattan Kapoor completed the acquisition of 0.38% stake in Shamrock Industrial Company Limited for INR 0.34 million. CI
28/10/25 Shamrock Industrial appoints Rahul Manoj Rajani as chief financial officer RE
28/10/25 Shamrock Industrial Company Limited Approves Appointment of Rahul Manoj Rajani as Chief Financial Officer, Effective October 28, 2025 CI
28/10/25 Shamrock Industrial Company Limited Announces Board Appointments, Effective October 28, 2025 CI
16/10/25 Shamrock Industrial Company Limited Announces Resignation of Jitesh Rameshchandra Khokhani as Chief Financial Officer, with Effect from Closure of Business Hours of October 16, 2025 CI
16/10/25 Shamrock Industrial Company Limited Announces Board Resignations, with Effect from October 16, 2025 CI
12/08/25 Shamrock Industrial Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
1 month+4.97%
3 months+15.67%
6 months+27.47%
Current year+27.47%
1 week 24.73
Extreme 24.73
24.73
1 month 24.73
Extreme 24.73
24.73
Current year 19.4
Extreme 19.4
24.73
1 year 16.77
Extreme 16.77
24.73
3 years 3.34
Extreme 3.34
24.73
5 years 3.16
Extreme 3.16
24.73
10 years 3.16
Extreme 3.16
24.73
Manager TitleAgeSince
Chief Executive Officer - 15/10/2025
Director of Finance/CFO - 27/10/2025
Chief Operating Officer - 27/10/2025
Director TitleAgeSince
Director/Board Member - 21/06/2021
Director/Board Member - 20/04/2022
Director/Board Member - 15/10/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+47.47%+604.56% 1.41M
-0.52%+3.21%+85.02%+161.12% 1,057B
+0.88%+1.13%+51.13%+49.76% 625B
+0.89%-1.95%+23.73%+63.67% 435B
+0.71%+3.87%+47.45%+38.68% 363B
+0.64%-0.49%+35.39%+40.21% 296B
+0.39%-5.83%+8.64%+9.28% 249B
+1.51%+6.69%+44.34%+62.47% 222B
+3.92%-0.46%-1.21%-44.09% 209B
+1.80%+2.30%+20.79%+65.13% 165B
Average +1.18%+0.78%+36.27%+105.08% 362.08B
Weighted average by Cap. +1.12%+1.22%+48.34%+75.33%

Financials

2024 2025
Net sales 1.12 0.01 0.01 0.01 0.01 0.02 0.02 0.11 0.04 0.56 0.04 0.04 1.85 -
Net income -406K -4.27K -3.69K -3.45K -3.16K -5.95K -6.04K -40.43K -15.87K -203K -16.02K -15.67K -673K -1.26M -13.24K -11.45K -10.69K -9.81K -18.45K -18.75K -125K -49.25K -632K -49.72K -48.63K -2.09M
Net Debt -9.31M -97.82K -84.62K -79.02K -72.49K -136K -139K -927K -364K -4.67M -367K -359K -15.43M -137K -1.44K -1.25K -1.16K -1.07K -2.01K -2.04K -13.64K -5.35K -68.67K -5.41K -5.29K -227K
Logo Shamrock Industrial Company Limited
Shamrock Industrial Company Limited is an India-based pharmaceuticals company. The Company offers a diverse range of manufacturing of pharmaceuticals and drugs products and allied business activities. It offers its products for various therapeutic uses, including anti-coagulants (anti-platelet), radio-protective agents, platelet regulator, anti-depressants, anti-neo plastics and immunosuppressants, antihistamines, sympathomimetics, anti-hypertensives, diuretic, anti-diabetic, calcium regulating agents, local anesthetics and anti-bacterial. Its active pharmaceutical ingredient (API) product list (manufactured) includes acenocomarol, amifostine, ciclopirox, cilazapril, losartan potassium, metaxalone, metoprolol succinate and pregabalin. The Company's API product list (contract manufactured) includes abacavir, acarbose, oxaliplatin, oxaprozin, finasteride, frusemide and colchicine.
Employees
1
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. SHAMROIN Stock